Provepharm Life Solutions

Provepharm Life Solutions

Philippe Goupil established Provepharm Life Solutions in 2002 as a pharmaceutical development firm headquartered in Marseille, France. The company initially focused on reformulating and repurposing existing drugs for hospital use, a strategy that generated a portfolio of patented products and associated royalty streams. The firm's investment strategy centers on life sciences, spanning drug development, manufacturing, and intellectual property management. Provepharm holds marketed drugs such as Bludigo (methylene blue injection) and Hexalen (altretamine capsules), the latter acquired from MGI Pharma. Geographic coverage includes European and North American markets, with regulatory filings through the FDA and EMA (per public record). Provepharm employs under 50 professionals across its operations and maintains its sole office in Marseille. In 2022, the firm was acquired by private equity firm Ampersand Capital Partners, though the Goupil family retained a significant stake and operating control (per Ampersand, 2022). The firm also operates a philanthropic arm, the Provepharm Foundation. A distinguishing structural feature is Provepharm's hybrid model as an operating company with family-office capital allocation. The firm's revenue from pharmaceutical sales provides a steady capital base for reinvestment into R&D and acquisitions, unlike a pure single-family office managing external wealth. This integrated operating-and-investing architecture allows the Goupil family to directly control both drug development timelines and return profiles.